Worldwide Industry for Pharmaceutical Treatments for Mental Health Disorders to 2025 - Snapshot of Products in Phase III Development for Selected Psychiatric Disorders
This new report on the market for pharmaceutical treatments for mental health disorders provides a brief overview of the pharmaceutical markets, current and future treatments, as well as drug failure/withdrawals and barriers to entry. It examines changes in healthcare regulation and guidance in the development of new agents and reviews activity in mergers and acquisitions that will help to change future treatment paradigms.
Report Includes:
46 data tables and 12 additional tables
An overview of the global markets for pharmaceutical treatments for mental health disorders
Analyses of market trends, with data from 2019, 2020 and projections of compound annual growth rates (CAGRs) through 2025
Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
Description of biological factors such as anatomical, chemical and genetic traits, and psychological reasons such as conflict or trauma on the mental health and discussion on effect of COIVD-19 pandemic, social distancing and social isolation on the mental health conditions
A look at the markets for treatment of psychiatric disorders such as depression, anxiety and obsessive-compulsive disorder (OCD) and their co relation with COVID-19
Details of technological advances and improvement in the development of pharmacological treatments, digital therapeutics (DTx) and cognitive behavioural therapy (CBT)
Information on tele mental health software such as ReSet, Pears Somryst and Alkili's EndeavorRx which offers personalized treatment strategies and behavioural healthcare platform which plays an important role in the management of mental health disorders
Snapshot of leading mental health conditions, and products in phase III development for selected psychiatric disorders
Analysis of recent product developments including pharmacological and digital therapeutics, late-stage pipeline products and points of differentiation from existing therapies
Market share analysis of the key companies of the industry, their strategic profiling, their competitive landscape and their detailed company profiles including, Eli Lilly, Johnson & Johnson, Pfizer, Takeda, and Shionogi
It is estimated that mental health disorders affect one in four adults each year and are the leading cause of impairment and disability across the globe. Mental health disorders refer to a wide range of mental health disorders that affect mood, thinking and behavior. These conditions can occur either due to biological factors such as anatomical, chemical and genetic traits, or psychological reasons such as conflict or trauma.
Market research suggests that mental health conditions are likely to rise in the near future due to the consequences of COIVD-19 pandemic, social distancing and social isolation.
Reasons for Doing This Study:
The treatment of mental health disorders is complex and often involves pharmacological and behavioral interventions. Diagnosis can be challenging, as symptoms can be complicated by comorbid conditions. This report highlights the current diagnosis and treatment of leading mental health disorders and highlights the clinical unmet needs that new formulations, treatment combinations and new mechanisms of action to address or change the future treatment paradigm of these prevalent conditions. There are also several external factors, including changing regulatory guidance and the impact of the COVID-19 pandemic, which may increase access and reimbursement to medication and digital therapeutics to address unmet medical needs.
Key Topics Covered:
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Custom Research
Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Depression and Anxiety
Market Landscape
Segmentation by Drug Class
Segmentation by Company
Prevalence of Disorders
Diagnosis
Current Treatments
Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
The "U.S. Augmented and Virtual Reality Headset Market - A Country Analysis: Focus on Application, Product, and Country - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The U.S. augmented and virtual...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amplitude, Inc. ("Amplitude" or the "Company") and reminds investors of the April 15, 2024 deadline to seek the role of lead plaintiff in a...
The "Thailand Construction Equipment Rental Market - Strategic Assessment & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering.
The Thailand construction equipment rental market is expected to reach a value of $428.7...
The following is written by Dr. Tracy D. Hall, President of Southwest Tennessee Community College:
The Chronicle of Higher Education released in July 2023 a publication entitled "College as a Public Good: Making the case through community...
The "PCR Markets. Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place. With Executive and Consultant Guides, Including Customized Forecasting and Analysis. 2023 to 2027" report has been added to...